Asprosin: A systemic fasting-induced adipokine with widespread physiological effects and therapeutic potential
Asprosin, a fasting-induced adipokine derived from the C-terminal cleavage of profibrillin-1, modulates glucose homeostasis and appetite and participates in multiple physiological and pathophysiological processes. White adipose tissue is the main source of circulating asprosin, although pancreatic beta (β)-cells, salivary glands, and cartilage also produce it. Asprosin stimulates hepatic glucose release via olfactory receptor (OLFR734)-dependent G protein–cAMP–PKA signaling and promotes feeding by activating hypothalamic Agouti-related peptide (AgRP) neurons; dysregulated asprosin levels associate with obesity, insulin resistance, type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), and reproductive and cardiovascular disorders. This narrative review summarizes the discovery, sources, signaling mechanisms, systemic effects (endocrine/metabolic, gastrointestinal, nervous, cardiovascular, respiratory, reproductive, renal, musculoskeletal), and therapeutic implications of asprosin, and highlights areas where further research is needed.
Authors
- Mihret Getnet (ORCID: https://orcid.org/0000-0001-7553-1429)
- Hailu Aragie (ORCID: https://orcid.org/0000-0002-0700-2952)
- Lemlemu Maru (ORCID: https://orcid.org/0009-0002-8173-7751)
- Hadush Tinsiae Kahsay (ORCID: https://orcid.org/0000-0002-8245-0229)
- Mitku Mamo Tadergew
Institutions
- Aksum University (ET)
- University of Gondar (ET)
Publication Details
- Journal
- Biochemistry and Biophysics Reports
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1016/j.bbrep.2026.102884
- Primary Topic
- Adipokines, Inflammation, and Metabolic Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00